Tenax Therapeutics, Inc.TENXNASDAQ
Loading
Operating Cash Flow Growth TrendStable
Percentile Rank23
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

Percentile
P23
Within normal range
vs 5Y Ago
-2.8x
Contraction
Streak
2 qtr
Consecutive declineStable
PeriodValue
Q4 2025-46.53%
Q3 2025-46.18%
Q2 202510.10%
Q1 2025-97.53%
Q4 2024-14.24%
Q3 2024-1.86%
Q2 202441.33%
Q1 2024-339.83%
Q4 202343.56%
Q3 2023-125.49%
Q2 202346.49%
Q1 202325.43%
Q4 202230.56%
Q3 20222.92%
Q2 2022-16.80%
Q1 2022-6.11%
Q4 20218.38%
Q3 2021-63.76%
Q2 202142.72%
Q1 2021-62.07%
Q4 202016.68%
Q3 2020-7.02%
Q2 202016.55%
Q1 2020-54.73%
Q4 20193.15%
Q3 20196.92%
Q2 201910.22%
Q1 2019-78.08%
Q4 201823.02%
Q3 2018-30.99%
Q2 201823.79%
Q1 2018-21.56%
Q4 2017-4.58%
Q3 201778.09%
Q2 2017-38.59%
Q1 2017-30.02%
Q4 201627.47%
Q3 201617.13%
Q2 2016-55.59%
Q1 2016-66935.99%